Serum NfL and GFAP are weak predictors of long-term multiple sclerosis prognosis: A 6-year follow-up.

MLA

Ayrignac, Xavier, et al. “Serum NfL and GFAP Are Weak Predictors of Long-Term Multiple Sclerosis Prognosis: A 6-Year Follow-Up.” Multiple Sclerosis and Related Disorders, vol. 89, Sept. 2024, p. 105747. EBSCOhost, https://doi.org/10.1016/j.msard.2024.105747.

APA

Ayrignac, X., Aouinti, S., Vincent, T., Carra-Dallière, C., Charif, M., Duflos, C., Hirtz, C., Dos Santos, A., Menjot de Champfleur, N., Labauge, P., & Lehmann, S. (2024). Serum NfL and GFAP are weak predictors of long-term multiple sclerosis prognosis: A 6-year follow-up. Multiple Sclerosis and Related Disorders, 89, 105747. https://doi.org/10.1016/j.msard.2024.105747

Chicago

Ayrignac, Xavier, Safa Aouinti, Thierry Vincent, Clarisse Carra-Dallière, Mahmoud Charif, Claire Duflos, Christophe Hirtz, et al. 2024. “Serum NfL and GFAP Are Weak Predictors of Long-Term Multiple Sclerosis Prognosis: A 6-Year Follow-Up.” Multiple Sclerosis and Related Disorders 89 (September): 105747. doi:10.1016/j.msard.2024.105747.